SkinBioTherapeutics PLC SkinBioTherapeutics involved in new research grant
May 29 2018 - 2:01AM
RNS Non-Regulatory
TIDMSBTX
SkinBioTherapeutics PLC
29 May 2018
SkinBioTherapeutics plc
SkinBioTherapeutics to fulfil industrial partner role in skin
health research grant awarded to the University of Manchester
Manchester, UK - 29 May 2018 - SkinBioTherapeutics plc (AIM:
SBTX, the 'Company'), a life science company focused on skin
health, announces its collaboration as industrial partner in a
grant awarded by the Biotechnology and Biological Sciences Research
Council (BBSRC) to The University of Manchester (the
'University').
The grant of approximately GBP600k provides the University with
non-dilutive funding for up to three years to investigate how
ageing affects the skin and in particular, its microbiome. In the
gut, it is currently understood that certain fibres can promote the
growth of beneficial bacteria (called a 'prebiotic effect') but
research is needed to determine how this principle applies to skin
health and which molecules could be prebiotic for the skins
microbiome.
BBSRC awarded the grant to enable the University to carry out
research which could lead to the development of novel ways to
improve the health of the skin microbiome during ageing and in
turn, support new approaches to prevent age-related skin conditions
and promote long-term skin health. Grant applications of this
nature are extremely competitive and the award is a strong external
validation of the capabilities of both the University and
SkinBioTherapeutics.
SkinBioTherapeutics is supporting the programme as the
industrial partner to further work in this exciting new area of the
skin microbiome. As industrial partner, SkinBioTherapeutics has
first refusal on any IP generated by the project. The Company will
be well placed to develop any relevant findings with the potential
to extend its current portfolio of indications in skin health,
anti-infection and repair.
Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:
"We have a long-standing relationship with the University, and I
am delighted this will continue through this latest collaboration.
It is testament to both teams that we have been successful with
such a prestigious award.
"Unlike the gut, virtually nothing is known about possible
prebiotics for skin. This study will provide the foundations for
developing novel prebiotic treatments for aged skin. This work is
very complementary to the work that we have already underway at
SkinBioTherapeutics in skin care, anti-infection and repair."
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0)
Dr. Cath O'Neill, CEO 161 468 2760
Doug Quinn, CFO
Instinctif Partners (Media Relations) Tel: +44 (0)
Melanie Toyne-Sewell / Deborah 20 7457 2020
Bell SkinBio@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEASSSAEEPEFF
(END) Dow Jones Newswires
May 29, 2018 02:01 ET (06:01 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024